New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey

OBJECTIVE: Recent clinical studies have shown that anticoagulant therapy might be effective only in specific at-risk subgroups of patients with sepsis and coagulation dysfunction. The definition of sepsis was recently modified and old scoring systems may no longer be proper for the diagnosis of sepsis-associated coagulopathy. The aim of this study was to evaluate prognostic factors in patients diagnosed as sepsis and coagulopathy according to the new sepsis definition and assess their accuracy in comparison to existing models.
DESIGN, SETTING AND SUBJECTS: The data set was obtained from a post-marketing survey examining recombinant human soluble thrombomodulin and offered by Japanese Society on Thrombosis and Hemostasis. A total of 1498 patients with sepsis and coagulopathy complications who were treated with recombinant thrombomodulin were analyzed in this study.
MAIN OUTCOME MEASURES: The platelet count, prothrombin time (PT) ratio, fibrinogen and fibrin degradation products (FDP), ...

研究目的：近期临床研究表明，抗凝治疗或许仅对脓毒症（sepsis）合并凝血功能障碍的特定高危亚组患者有效。当前脓毒症的定义已完成修订，旧版评分系统或不再适用于脓毒症相关凝血病的诊断。本研究旨在针对符合新版脓毒症定义的脓毒症合并凝血功能障碍患者，评估其预后影响因素，并与现有预测模型对比，验证相关指标的诊断准确性。
研究设计、研究场景与研究对象：本数据集来源于日本血栓与止血学会（Japanese Society on Thrombosis and Hemostasis）提供的一项针对重组人可溶性血栓调节蛋白的上市后调研。本研究共纳入1498例接受重组血栓调节蛋白治疗的脓毒症合并凝血功能障碍并发症患者进行分析。
主要观察指标：血小板计数、凝血酶原时间（prothrombin time, PT）比值、纤维蛋白原及纤维蛋白降解产物（fibrin and fibrin degradation products, FDP）……